Bind Preps For Important Catalysts In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The nanomedicine developer said it expects to have results from two Phase II trials before the end of the year potentially validating its technology platform during its first year-end sales and earnings call since completing an IPO in September.
You may also be interested in...
Amgen, Bind Partner To Develop Targeted Nanomedicine For Cancer
Amgen will develop a targeted cancer medicine using a novel Accurin from Bind’s nanomedicine platform and one of its proprietary kinase inhibitors; the deal represents the first major partnership applying a nanomedicine technology to a molecularly targeted drug.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.